Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients

Molecular portraits of numerous tumors have flooded oncologists with vast amounts of data. In parallel, effective inhibitors of central pathways have shown great clinical benefit. Together, this promises potential clinical benefits to otherwise end-stage cancer patients. Here, we report a clinical s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zick, Aviad, Peretz, Tamar, Lotem, Michal, Hubert, Ayala, Katz, Daniela, Temper, Mark, Rottenberg, Yakir, Uziely, Beatrice, Nechushtan, Hovav, Meirovitz, Amichai, Sonnenblick, Amir, Sapir, Eli, Edelman, David, Goldberg, Yael, Lossos, Alexander, Rosenberg, Shai, Fried, Iris, Finklstein, Ruth, Pikarsky, Eli, Goldshmidt, Hanoch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440149/
https://www.ncbi.nlm.nih.gov/pubmed/28514312
http://dx.doi.org/10.1097/MD.0000000000006931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440149/
https://www.ncbi.nlm.nih.gov/pubmed/28514312
http://dx.doi.org/10.1097/MD.0000000000006931

Ejemplares similares